Explore

Trendline Trendline
University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response

University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response

University of Houston and MIT Develop mRNA-Based Cancer Vaccine Strategy Enhancing T-Cell Response
Trendline Trendline
Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York

Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York

Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Rapid Read Rapid Read
Discovery of HOXD13 Protein as a Key Driver in Melanoma Growth and Survival

Discovery of HOXD13 Protein as a Key Driver in Melanoma Growth and Survival

A study conducted by scientists at the NYU Grossman School of Medicine has identified the transcription factor HOXD13 as a critical protein in the growth and survival of melanomas, a type of skin cancer. This protein plays a vital role in promoting the formation of new blood vessels to supply tumors with oxygen and nutrients, while also inhibiting immune T cells from attacking the tumor. The research demonstrated that blocking HOXD13 activity allows more T cells to enter the tumor, suggesting potential therapeutic strategies. The study, supported by NIH grants, was published in Cancer Discovery.
Trendline Trendline
ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026

ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026

ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026
Trendline Trendline
ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment
Rapid Read Rapid Read
SpacePharma's Innovative Cancer Research in Microgravity Advances on International Space Station

SpacePharma's Innovative Cancer Research in Microgravity Advances on International Space Station

SpacePharma, an Israeli company, has launched a new experimental laboratory to the International Space Station (ISS) aboard a SpaceX Dragon cargo spacecraft. This lab is designed for conducting biological experiments under microgravity conditions, focusing on cancer research. One experiment involves brain-tissue organoids created from cancer patients' tissue samples, aiming to identify cancer biomarkers. Another experiment, led by Roche Pharmaceuticals and Harvard University, seeks to grow lung-cell tissue with sensors for lung cancer treatment. These experiments are funded by the European Space Agency and represent SpacePharma's 14th mission to space.
Trendline Trendline
OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset
SB Nation SB Nation
Celtics’ Jaylen Brown questions NBA’s need for a social justice award

Celtics’ Jaylen Brown questions NBA’s need for a social justice award

"I don't really feel like you need to be rewarded for your responsibility,” Brown told his Twitch livestream Sunday night.
Rapid Read Rapid Read
FDA Approves Signatera CDx as Companion Diagnostic for Muscle-Invasive Bladder Cancer

FDA Approves Signatera CDx as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Natera, Inc. has announced that the FDA has approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer (MIBC). This marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions. The approval is based on the Phase III IMvigor011 trial, which showed that Signatera MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival and overall survival. The test allows for precision interventions for MRD-positive patients while sparing MRD-negative patients from unnecessary treatment.
Rapid Read Rapid Read
FDA Approves Genentech's Tecentriq for Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment

FDA Approves Genentech's Tecentriq for Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment

The U.S. Food and Drug Administration (FDA) has approved Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) after cystectomy. This approval marks the first ctDNA MRD-guided therapy, allowing healthcare professionals to tailor treatment to improve clinical benefits and reduce unnecessary interventions. The decision was based on the Phase III IMvigor011 study, which demonstrated that Tecentriq reduced the risk of disease recurrence or death by 36% and the risk of death by 41% in patients with detectable ctDNA MRD. The study utilized Natera's Signatera CDx personalized MRD assay to identify molecular evidence of cancer in the blood, enabling selective deployment of adjuvant immunotherapy.
Rapid Read Rapid Read
Ebola Outbreak in Africa Highlights Urgent Need for New Vaccines Amid WHO Funding Cuts

Ebola Outbreak in Africa Highlights Urgent Need for New Vaccines Amid WHO Funding Cuts

A recent outbreak of the Ebola virus in the Democratic Republic of the Congo (DRC) and Uganda has been declared a public health emergency of international concern by the World Health Organization (WHO). The outbreak involves the Bundibugyo strain of Ebola, which has a mortality rate of 20 to 50 percent. As of May 17, 2026, there are 336 suspected cases and 88 deaths reported. The outbreak has underscored the urgent need for new vaccines, particularly as the WHO faces significant funding cuts following the U.S. withdrawal of financial support in early 2025. This has led to reduced staffing and resources, impacting the organization's ability to respond effectively to such health crises.